Evidence-Based Oncology > September

Evidence-Based Oncology - September

August 17, 2012 – This article was sponsored by Eisai Inc. The 2012 Eisai Oncology Digest was commissioned and funded by Eisai Inc.
September 17, 2012
Michael E. Chernew, PhD; Lee N. Newcomer, MD, MHA; and Sandra M. Swain, MD; examine the treatment benefits, cost concerns, and insurance coverage strategies for pertuzumab.
September 18, 2012 – Bruce A. Feinberg, DO; James Lang, PharmD, MBA; James Grzegorczyk, MS, RPh; Donna Stark, RPh, MBA; Thomas Rybarczyk, RN, BSN; Thomas Leyden, MBA; Joseph Cooper; Thomas Ruane, MD; Scott Milligan, PhD;
September 18, 2012 – Marj P. Zimmerman, MS, BSPharm, RPh; and Stanton R. Mehr
September 20, 2012 – Silas Inman
September 20, 2012 – Beth Fand Incollingo
September 20, 2012 – Stanton R. Mehr
September 20, 2012 – Michael Marlan Mohundro, PharmD; and Brice Labruzzo Mohundro, PharmD
Targeted Therapies to Further Improve Outcomes
September 20, 2012 – Linda D. Bosserman, MD, FACP; Diana Verrilli; and Wendy McNatt
September 20, 2012 – John D. Sprandio, MD, FACP
September 20, 2012 – Kim Farina, PhD
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome to the new and improved AJMC.com, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!